Is the price fair?
What WRBY's price assumes
Warby Parker Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 2.97× revenue.
2.97
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 1.2%
Free cash flow yield · Medical Instruments & Supplies median 3.7%
- Growth the price implies
- +24%
Growth the price implies · The price pays for +24% free cash flow growth a year for a decade; revenue has grown +13% a year over the last three.
- Price / book
- 7.04
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 7.04
- EV / EBIToperating margin −0.69%: the multiple describes the denominator
- not meaningful
- Free cash flow, trailing twelve months
- $39M
- Market capitalisation
- $3.19B
- 3-year revenue growth
- +13%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Instruments & Supplies
Ranks #25 of 27 by Smart Score